Evaluation of Fused Pyrrolothiazole Systems as Correctors of Mutant CFTR Protein.

Virginia Spanò, Marilia Barreca, Vincenzo Cilibrasi, Michele Genovese, Mario Renda, Alessandra Montalbano, Luis Juan Vicente Galietta, Paola Barraja

Molecules (Basel, Switzerland) 2021 Feb 26

filter terms:

Cystic fibrosis (CF) is a genetic disease caused by mutations that impair the function of the CFTR chloride channel. The most frequent mutation, F508del, causes misfolding and premature degradation of CFTR protein. This defect can be overcome with pharmacological agents named "correctors". So far, at least three different classes of correctors have been identified based on the additive/synergistic effects that are obtained when compounds of different classes are combined together. The development of class 2 correctors has lagged behind that of compounds belonging to the other classes. It was shown that the efficacy of the prototypical class 2 corrector, the bithiazole corr-4a, could be improved by generating conformationally-locked bithiazoles. In the present study, we investigated the effect of tricyclic pyrrolothiazoles as analogues of constrained bithiazoles. Thirty-five compounds were tested using the functional assay based on the halide-sensitive yellow fluorescent protein (HS-YFP) that measured CFTR activity. One compound, having a six atom carbocyle central ring in the tricyclic pyrrolothiazole system and bearing a pivalamide group at the thiazole moiety and a 5-chloro-2-methoxyphenyl carboxamide at the pyrrole ring, significantly increased F508del-CFTR activity. This compound could lead to the synthesis of a novel class of CFTR correctors.

Citation

Virginia Spanò, Marilia Barreca, Vincenzo Cilibrasi, Michele Genovese, Mario Renda, Alessandra Montalbano, Luis Juan Vicente Galietta, Paola Barraja. Evaluation of Fused Pyrrolothiazole Systems as Correctors of Mutant CFTR Protein. Molecules (Basel, Switzerland). 2021 Feb 26;26(5)